Achillion Pharmaceuticals, Inc. (ACHN) Analysts See $-0.14 EPS

April 21, 2018 - By Darrin Black

Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) LogoInvestors sentiment increased to 2.08 in Q4 2017. Its up 1.12, from 0.96 in 2017Q3. It improved, as 10 investors sold Achillion Pharmaceuticals, Inc. shares while 28 reduced holdings. 34 funds opened positions while 45 raised stakes. 110.36 million shares or 4.96% more from 105.14 million shares in 2017Q3 were reported.
4.73 million are owned by Dimensional Fund Advisors Limited Partnership. Qcm Cayman Limited owns 14,756 shares for 0.17% of their portfolio. The Ontario – Canada-based Comml Bank Of Montreal Can has invested 0% in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN). Qs Invsts Ltd Limited Liability Company holds 0.01% or 479,363 shares. Barclays Public Limited Co invested 0% in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN). 46,345 are owned by Legal And General Group Public Ltd Com. State Street Corp, a Massachusetts-based fund reported 5.71M shares. Tiaa Cref Inv Lc reported 0% in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN). Baker Bros Advsr Limited Partnership has 0.07% invested in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) for 2.86M shares. Royal National Bank Of Canada reported 0% of its portfolio in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN). Citigroup owns 0% invested in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) for 235,340 shares. 96,492 are owned by Connor Clark And Lunn Limited. Alliancebernstein Ltd Partnership has invested 0% in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN). 14,300 are held by Hbk Invests Ltd Partnership. Bourgeon Capital Limited Co invested in 48,504 shares or 0.08% of the stock.

Analysts expect Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) to report $-0.14 EPS on May, 3.They anticipate $0.01 EPS change or 6.67 % from last quarter’s $-0.15 EPS. After having $-0.17 EPS previously, Achillion Pharmaceuticals, Inc.’s analysts see -17.65 % EPS growth. The stock increased 0.55% or $0.02 during the last trading session, reaching $3.65. About 404,563 shares traded. Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) has declined 2.57% since April 21, 2017 and is downtrending. It has underperformed by 14.12% the S&P500.

Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) Ratings Coverage

Among 4 analysts covering Achillion Pharmaceuticals (NASDAQ:ACHN), 1 have Buy rating, 0 Sell and 3 Hold. Therefore 25% are positive. Achillion Pharmaceuticals had 5 analyst reports since October 23, 2017 according to SRatingsIntel. The firm has “Hold” rating by FBR Capital given on Wednesday, February 7. Leerink Swann maintained Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) rating on Monday, December 11. Leerink Swann has “Buy” rating and $5.0 target. Robert W. Baird maintained Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) rating on Monday, October 23. Robert W. Baird has “Hold” rating and $4.0 target. FBR Capital maintained Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) on Friday, February 23 with “Hold” rating.

Achillion Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes small molecule drug therapies for infectious diseases and immune system disorders in the United States and internationally. The company has market cap of $503.31 million. The Company’s drug candidates for treating chronic hepatitis C virus infection comprise Odalasvir, a NS5A inhibitor, which has completed Phase IIa clinical trials; ACH-3422, a NS5B nucleotide polymerase inhibitor; and Sovaprevir, a NS3 protease inhibitor that has completed Phase II clinical trial. It currently has negative earnings. The firm is also developing ACH-4471, a complement factor D inhibitor, which is in Phase I clinical trial to treat patients with paroxysmal nocturnal hemoglobinuria and C3G, a disease resulting from alternative pathway over-activation; and other factor D inhibitors.

Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: